Your browser doesn't support javascript.
loading
Dependence on the Pyrimidine Biosynthetic Enzyme DHODH Is a Synthetic Lethal Vulnerability in Mutant KRAS-Driven Cancers.
Koundinya, Malvika; Sudhalter, Judith; Courjaud, Albane; Lionne, Bruno; Touyer, Gaetan; Bonnet, Luc; Menguy, Isabelle; Schreiber, Isabelle; Perrault, Christelle; Vougier, Stephanie; Benhamou, Brigitte; Zhang, Bailin; He, Timothy; Gao, Qiang; Gee, Patricia; Simard, Daniel; Castaldi, M Paola; Tomlinson, Ronald; Reiling, Stephan; Barrague, Matthieu; Newcombe, Richard; Cao, Hui; Wang, Yanjun; Sun, Fangxian; Murtie, Joshua; Munson, Mark; Yang, Eric; Harper, David; Bouaboula, Monsif; Pollard, Jack; Grepin, Claudine; Garcia-Echeverria, Carlos; Cheng, Hong; Adrian, Francisco; Winter, Christopher; Licht, Stuart; Cornella-Taracido, Ivan; Arrebola, Rosalia; Morris, Aaron.
Afiliación
  • Koundinya M; Cancer Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA.
  • Sudhalter J; Cancer Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA.
  • Courjaud A; LGCR-LIT, Sanofi, Vitry-Sur-Seine 94400, France.
  • Lionne B; LGCR-LIT, Sanofi, Vitry-Sur-Seine 94400, France.
  • Touyer G; LGCR-LIT, Sanofi, Vitry-Sur-Seine 94400, France.
  • Bonnet L; LGCR-LIT, Sanofi, Vitry-Sur-Seine 94400, France.
  • Menguy I; LGCR-LIT, Sanofi, Vitry-Sur-Seine 94400, France.
  • Schreiber I; LGCR-LIT, Sanofi, Vitry-Sur-Seine 94400, France.
  • Perrault C; LGCR-LIT, Sanofi, Vitry-Sur-Seine 94400, France.
  • Vougier S; LGCR-LIT, Sanofi, Vitry-Sur-Seine 94400, France.
  • Benhamou B; LGCR-LIT, Sanofi, Vitry-Sur-Seine 94400, France.
  • Zhang B; Biochemistry, Bioanalytics, and Chemical Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA.
  • He T; Biochemistry, Bioanalytics, and Chemical Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA.
  • Gao Q; Biochemistry, Bioanalytics, and Chemical Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA.
  • Gee P; Biochemistry, Bioanalytics, and Chemical Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA.
  • Simard D; Biochemistry, Bioanalytics, and Chemical Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA; Chemistry, Oncology Division, Sanofi, Cambridge, MA 02138, USA.
  • Castaldi MP; Chemistry, Oncology Division, Sanofi, Cambridge, MA 02138, USA.
  • Tomlinson R; Chemistry, Oncology Division, Sanofi, Cambridge, MA 02138, USA.
  • Reiling S; LGCR-SDI, Oncology Division, Sanofi, Cambridge, MA 02138, USA.
  • Barrague M; LGCR, Oncology Division, Sanofi, Cambridge, MA 02138, USA.
  • Newcombe R; Cancer Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA.
  • Cao H; TEM-BioInformatics, Oncology Division, Sanofi, Cambridge, MA 02138, USA.
  • Wang Y; In Vivo Pharmacology, Oncology Division, Sanofi, Cambridge, MA 02138, USA.
  • Sun F; In Vivo Pharmacology, Oncology Division, Sanofi, Cambridge, MA 02138, USA.
  • Murtie J; In Vivo Pharmacology, Oncology Division, Sanofi, Cambridge, MA 02138, USA.
  • Munson M; LGCR, Oncology Division, Sanofi, Cambridge, MA 02138, USA.
  • Yang E; TEM-BioInformatics, Oncology Division, Sanofi, Cambridge, MA 02138, USA.
  • Harper D; Cancer Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA.
  • Bouaboula M; Cancer Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA.
  • Pollard J; TEM-BioInformatics, Oncology Division, Sanofi, Cambridge, MA 02138, USA.
  • Grepin C; LGCR-LIT, Sanofi, Vitry-Sur-Seine 94400, France.
  • Garcia-Echeverria C; Biochemistry, Bioanalytics, and Chemical Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA.
  • Cheng H; Biochemistry, Bioanalytics, and Chemical Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA.
  • Adrian F; Cancer Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA.
  • Winter C; Cancer Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA.
  • Licht S; Biochemistry, Bioanalytics, and Chemical Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA. Electronic address: sslicht@gmail.com.
  • Cornella-Taracido I; Chemistry, Oncology Division, Sanofi, Cambridge, MA 02138, USA.
  • Arrebola R; LGCR-LIT, Sanofi, Vitry-Sur-Seine 94400, France.
  • Morris A; Cancer Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA. Electronic address: aaronjmorris@gmail.com.
Cell Chem Biol ; 25(6): 705-717.e11, 2018 06 21.
Article en En | MEDLINE | ID: mdl-29628435
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Pirimidinas / Proteínas Proto-Oncogénicas p21(ras) / Oxidorreductasas actuantes sobre Donantes de Grupo CH-CH Límite: Animals / Female / Humans Idioma: En Revista: Cell Chem Biol Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Pirimidinas / Proteínas Proto-Oncogénicas p21(ras) / Oxidorreductasas actuantes sobre Donantes de Grupo CH-CH Límite: Animals / Female / Humans Idioma: En Revista: Cell Chem Biol Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos